论文部分内容阅读
目的:观察艾普拉唑肠溶片上市后珠海医院的使用情况,评估其安全性及相关影响因素。方法:选择使用艾普拉唑肠溶片治疗的患者,随访调查不良事件和不良反应发生情况。结果:对1 969例次使用艾普拉唑肠溶片的患者进行随访调查,出现38例共发生48次不良事件,发生率为1.93%;33例共40次不良反应,发生率为1.68%,其主要表现为口干、头晕、口苦、腹泻、胸闷、恶心等。结论:使用艾普拉唑肠溶片未发生严重不良反应,相对比较安全。
Objective: To observe the use of ilaprazole enteric-coated tablets in Zhuhai Hospital after its listing, evaluate its safety and related factors. Methods: The patients treated with ilaprazole enteric-coated tablets were selected and followed up for the investigation of adverse events and adverse reactions. Results: The follow-up survey of 1 969 cases of patients taking ioprazole enteric-coated tablets was carried out. There were 38 adverse events in 48 cases (1.93%) and 33 (40 adverse reactions) in 1.38% , Which mainly manifested as dry mouth, dizziness, mouth pain, diarrhea, chest tightness, nausea and so on. Conclusion: There is no serious adverse reaction with ilaprazole enteric-coated tablets, which is relatively safe.